Jackie Fouse, Agios
December 21, 2020 07:00 AM ESTUpdated 08:43 AM
Deals

Agios piv­ots away from on­col­o­gy, auc­tion­ing off can­cer pipeline for $2B and shift­ing the spot­light in re­struc­tur­ing

John Carroll

Editor & Founder

Agios made its name as a can­cer drug de­vel­op­er un­der the leg­endary founder David Schenkein, who took the com­pa­ny from a fa­mous­ly blank sheet of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Af­ter Phase 3 de­pres­sion set­back, Neumo­ra paus­es two tri­als to make changes, scraps an­oth­er

No­vo Nordisk signs $354M part­ner­ship with AI-guid­ed biotech for ‘risky’ new meta­bol­ic mech­a­nisms

Pro­tag­o­nist, Takeda's prof­it shar­ing deal un­der spot­light af­ter Phase 3 blood dis­or­der tri­al win

AD­Cs from a decade-old Sin­ga­pore biotech find new life with $187M

Ab­b­Vie fi­nal­ly en­ters obe­si­ty race with $350M up­front for Gubra’s amylin

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times